Home / Recalls / Novartis Pharmaceuticals Corporation / D-0746-2026

D-0746-2026 Class II Ongoing

Recalled by Novartis Pharmaceuticals Corporation — East Hanover, NJ

FDA drug recall D-0746-2026 was initiated by Novartis Pharmaceuticals Corporation on Aug 4, 2026 and is designated Class II. Reason for recall: Failed Dissolution Specifications The recall status is ongoing.

Recall details

Product Type: Drugs
Report Date: Aug 19, 2026
Initiation Date: Aug 4, 2026
Voluntary/Mandated: Voluntary: Firm initiated

Product description

Diovan (valsartan) 160 mg, 90 tablets, Rx only, Manufactured by: Patheon Manufacturing Services LLC, Greenville, NC 27834, Distributed by: Novartis Pharmaceutical Corp, East Hanover, NJ 07936, NDC 0078-0359-34

Reason for recall

Failed Dissolution Specifications

Distribution pattern

US Nationwide

Code information

Lot AV5913C, Expiry: 6/2027

Source

Dataset: openFDA drug recall enforcement reports
FDA record: This recall in openFDA (JSON)
Enforcement Report: Search FDA's Enforcement Report for D-0746-2026
openFDA file date: Nov 10, 2026
Loaded by RegDataLab: Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Other recalls by Novartis Pharmaceuticals Corporation

D-0144-2024 Class I — SANDIMMUNE Oral Solution (cyclosporine oral solution, USP) 100 mg/mL, 50 mL… (Nov 22, 2023)
D-1543-2022 Class II — Neoral soft gelatin capsules (cyclosporine capsules, USP) Modified, 25 mg, Rx… (Sep 16, 2022)
D-0982-2022 Class III — Xiidra (lifitegrast ophthalmic solution), packaged in a) 60 Single-Use… (May 10, 2022)
D-0984-2022 Class III — Xiidra (lifitegrast ophthalmic solution) 5% PROFESSIONAL SAMPLE, packaged in a)… (May 10, 2022)
D-0983-2022 Class III — Xiidra (lifitegrast ophthalmic solution) 5%, packaged in a) 60 Single-Use… (May 10, 2022)
D-0985-2022 Class III — Xiidra (lifitegrast ophthalmic solution) 5% PROFESSIONAL SAMPLE, packaged in a)… (May 10, 2022)